A Four-Year Cross-Sectional Analysis of Dyslipidemia Prevalence on the Pamirs Plateau - Summary - MDSpire

A Four-Year Cross-Sectional Analysis of Dyslipidemia Prevalence on the Pamirs Plateau

  • By

  • Yisi Liu

  • Yue Shu

  • Xinyu Wang

  • Bin Li

  • Dai Su

  • Chaoji Huangfu

  • Zhu Huang

  • Yuxin Wang

  • Shuqian Zhang

  • Taiwei Wang

  • Chaoyue Gao

  • Lin Luo

  • Zexinyao Ren

  • Rui Wang

  • Yue Gao

  • Wei Zhou

  • December 29, 2025

  • 0 min

Share

Objective:

To characterize the prevalence and trends of dyslipidemia among residents of the Pamirs Plateau, focusing on ethnic variations and associated risk factors.

Key Findings:
  • Dyslipidemia prevalence varies significantly across different ethnic groups on the Pamirs Plateau.
  • Temporal trends indicate changes in lipid profiles over the four-year study period.
  • Environmental and lifestyle factors are associated with dyslipidemia risk in this high-altitude population.
Interpretation:

The study highlights the complex interplay between altitude, ethnicity, and lifestyle changes in influencing dyslipidemia risk, underscoring the need for targeted public health strategies.

Limitations:
  • The study is limited to a specific geographic area, which may affect the generalizability of findings.
  • Potential biases in self-reported data from questionnaires.
Conclusion:

This research provides essential insights into dyslipidemia among high-altitude populations, emphasizing the importance of considering ethnic and environmental factors in health assessments.

Original Source(s)

A Four-Year Cross-Sectional Analysis of Dyslipidemia Prevalence on the Pamirs Plateau

  • by Yisi Liu, Yue Shu, Xinyu Wang, Bin Li, Dai Su, Chaoji Huangfu, Zhu Huang, Yuxin Wang, Shuqian Zhang, Taiwei Wang, Chaoyue Gao, Lin Luo, Zexinyao Ren, Rui Wang, Yue Gao, Wei Zhou

  • December 29, 2025

Related Content

Visceral fat area and blood lipids in colorectal cancer: predictors of surgical risk and prognosis

The lipid–inflammation axis in rosacea: mechanistic insights and therapeutic implications

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.